Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial compared two treatments — sunitinib and capecitabine — in people with a specific type of cancer. A total of 238 people were assigned to the sunitinib group and 244 to the capecitabine group, making 482 participants in all. The trial's main goal was to measure "progression-free survival" — that is, how long participants went before their cancer showed signs of growing or spreading, or before they died from any cause, whichever came first. The reported data shows that, for the main measure, participants in the sunitinib group had a median progression-free survival of 2.8 months, compared with 4.2 months in the capecitabine group. (Median means the midpoint — half the participants in each group had a result above this figure and half below.) The reported data also shows that the time until the cancer first showed signs of growing was 2.8 months for sunitinib and 4.2 months for capecitabine. When looking at how many participants showed a measurable shrinkage in their tumours, 27 people in the sunitinib group and 40 people in the capecitabine group met this measure. Among those who did show a response, that response lasted a reported 6.9 months on average in the sunitinib group and 9.3 months in the capecitabine group. The average overall survival — time from the start of the trial until death from any cause — was reported as 15.3 months for sunitinib and 16.9 months for capecitabine. The time-to-tumour-response figures were not reported in the submitted data. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Breast Cancer Trial, Terminated
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You have been diagnosed with a type of breast cancer called breast adenocarcinoma
- You have already been treated with two specific types of chemotherapy drugs — an anthracycline and a taxane — either together or one after the other, whether that was before surgery, after surgery, or for advanced disease, with no more than one chemotherapy treatment course given for advanced disease
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You have received chemotherapy for advanced or metastatic breast cancer that went beyond treatments containing anthracyclines and taxanes, or you have had multiple separate courses of anthracycline or taxane treatments
- You have previously been treated with a drug called capecitabine (also known by the brand name Xeloda) at any point
Important: Always verify eligibility with the trial site directly before applying."
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial contact details on record
Principal Investigator: Pfizer CT.gov Call Center, Pfizer
Australian sites
This trial is not accepting new participants. These are the contact details ClinicalTrials.gov holds for it, kept here for reference. They are not an invitation to enrol, and the sites listed may no longer be running this trial.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, including 6 in Australia. They are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Progression-Free Survival (PFS)
Other options
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.